HDAC9 and acute myeloid leukemia: In the SJCRH phase 1 study for children with relapsed/refractory AML, venetoclax in combination with LDAC or HDAC was tested, and 360 mg/m2 venetoclax in combination with HDAC with or without idarubicin was determined to be the recommended phase 2 dose [89].